Specials Laboratory to supply clinical trials service to UK hospitals

Published: 29-Mar-2010

New service aims to meet the product manufacturing needs of NHS-based clinical trials

Hospitals across the UK will be able to take advantage of a new service aimed at meeting the product manufacturing needs of NHS-based clinical trials.

The Specials Laboratory, based in Northumberland, is to specialise in the supply of non-sterile products for use in small-scale clinical studies direct to hospitals after the specialist firm was licensed for the manufacture of investigational medicinal products (IMPs).

The new IMP service will assist clinical trial pharmacists and technicians, university medical schools and research doctors.

Operating from three MHRA-approved facilities, the company complies with current Good Manufacturing Practice (cGMP) and provides in-house Quality Person (QP) release, which will ensure products delivered to hospitals will be made to the highest possible quality standards.

‘Our quality-led manufacturing heritage allows us to produce virtually any non-sterile dosage form,’ said Robert Sludden, Quality and Technical Services Manager at The Specials Laboratory.

‘The company is also able to offer customers an experienced technical team that includes several pharmacists, senior pharmacy technicians and QPs – many with an extensive NHS background.’

With more hospitals opting to subcontract their IMP manufacturing needs, The Specials Laboratory is looking to build relationships with relevant NHS departments by offering to be their outsourced manufacturing partner supplying products for smaller clinical trials.

‘Hospital departments will be able to source a wide range of products from The Specials Laboratory for their IMP manufacturing requirements, including oral liquids, capsules, sachets, ointments, creams, ear and nasal drops, enema solutions, suppositories and pessaries,' added Sludden.

Set-up over a decade ago, The Specials Laboratory employs around 130 people and is a leading UK manufacturer of unlicensed medicines, which are bespoke for individual patients and supplied to community and hospital pharmacists and doctors.

See more

You may also like

Manufacturing

PCCA buys the specials business and Arjun Products from UDG Healthcare for £23.5m

Read more
Deal includes The Specials Laboratory and Craig & Hayward in Northumberland, UK

Trending Articles

  1. Accelerating technology transfer in biopharmaceutical manufacturing This article explores how structured, digitally enabled and integrated technology transfer frameworks are accelerating the commercialisation of complex biopharmaceutical modalities by enhancing precision, speed and regulatory readiness
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Using seamless, scalable technology to reshape the pharma supply chain and meet patients where they are This article explores how innovative technology can transform the pharmaceutical supply chain by ensuring timely access to vital medications for patients worldwide
  3. ACG wins Red Dot Design Award for breakthrough Personalised Medicine Concept ACG’s Personalised Medicine Concept (PMC) has earned the Red Dot Award for high design quality, recognising its pioneering approach to capsule-based personalised health solutions developed through the collaborative OneACG ecosystem
  4. Pfizer denied restraining order on rival Novo Nordisk in GLP-1 bidding war The Delaware Chancery Judge rejected Pfizer's request for a temporary restraining order, arguing that the company's objections to Novo's proposed deal weren't a legitimate reason for stopping the competitor's offer
  5. Novo Nordisk's Wegovy results in patients hitting key BMI and waist size targets New STEP UP trial data show that semaglutide enables people with obesity to achieve BMI and waist-to-height ratio targets linked to lower cardiovascular risk, alongside significant weight loss

You may also like

Manufacturing

PCCA buys the specials business and Arjun Products from UDG Healthcare for £23.5m

Deal includes The Specials Laboratory and Craig & Hayward in Northumberland, UK
Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development

EVerZom and GENFIT partner for research collaboration for liver failure candidate EViv

The agreement will support EVerZom’s dynamic development strategy and follows the recent announcement of a €10m financing round aimed at accelerating its clinical and partnering roadmap
You need to be a subscriber to read this article.
Click here to find out more.
Pharma 5.0

Three ways AI is changing the chemicals and materials industry

With AI technologies continuing to make their mark on almost every sector, the materials and chemicals industry is no exception, reports Cameron Ross, Senior Vice President of Generative AI at Elsevier
Manufacturing

Watson-Marlow to showcase advanced fluid path solutions at COMPAMED 2025

The fluid transfer solution specialist will highlight a variety of peristaltic pumps and associated fluid path technologies at this years COMPAMED 2025, taking place from 17-20 Nov in Düsseldorf, Germany
Research & Development

Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development

Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies
You need to be a subscriber to read this article.
Click here to find out more.
Personal Protection

Gas safety in smaller pharmaceutical facilities

Whether in the production process, for essential sterilisation or decontamination, the use of gases is fundamental in the pharmaceutical and biopharmaceutical industries. Each gas is, however, accompanied by risks and can pose significant hazards to the health of employees
Subscribe now